Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Total Current Liabilities (2023 - 2025)

Historic Total Current Liabilities for Tonix Pharmaceuticals Holding (TNXP) over the last 3 years, with Q3 2025 value amounting to $21.0 million.

  • Tonix Pharmaceuticals Holding's Total Current Liabilities rose 3853.5% to $21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.0 million, marking a year-over-year increase of 3853.5%. This contributed to the annual value of $18.3 million for FY2024, which is 305.55% down from last year.
  • As of Q3 2025, Tonix Pharmaceuticals Holding's Total Current Liabilities stood at $21.0 million, which was up 3853.5% from $19.1 million recorded in Q2 2025.
  • Tonix Pharmaceuticals Holding's 5-year Total Current Liabilities high stood at $22.0 million for Q2 2024, and its period low was $12.1 million during Q1 2025.
  • For the 3-year period, Tonix Pharmaceuticals Holding's Total Current Liabilities averaged around $17.9 million, with its median value being $18.4 million (2023).
  • Its Total Current Liabilities has fluctuated over the past 5 years, first soared by 5665.11% in 2024, then plummeted by 4069.05% in 2025.
  • Over the past 3 years, Tonix Pharmaceuticals Holding's Total Current Liabilities (Quarter) stood at $18.9 million in 2023, then fell by 3.06% to $18.3 million in 2024, then increased by 14.88% to $21.0 million in 2025.
  • Its Total Current Liabilities stands at $21.0 million for Q3 2025, versus $19.1 million for Q2 2025 and $12.1 million for Q1 2025.